CDR-Life has announced key advancements in its M-gager® programs targeting solid tumors, highlighting notable progress in its mission to develop innovative antibody fragment-based immunotherapies for challenging cancers.
First Patient Dosed with CDR404 CDR-Life has dosed its first patient with CDR404, a novel bispecific T cell engager (TCE) targeting the MAGE-A4 protein, which is associated with cancer cells. The Phase 1 study (NCT06402201) is enrolling patients with MAGE-A4+ solid tumors in the U.S. and Europe to assess the safety, tolerability, and early anti-tumor activity of CDR404, focusing on cancers like squamous cell carcinomas where MAGE-A4 is prevalent.
New Clinical Candidate: CDR813 The company has identified CDR813, a TCE targeting the PRAME antigen, as a promising new clinical candidate. PRAME is expressed in various solid tumors, including lung, ovarian, melanoma, and endometrial cancers, but has minimal expression in healthy tissues. Preclinical studies show CDR813 has strong pharmacological and manufacturability attributes, positioning it as a potential best-in-class therapy.
A poster detailing this research will be presented at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona.
Poster Presentation Details:
- Title: Highly Potent and Specific Bivalent T Cell Engager (TCE) Targeting PRAME on HLA-A*02:01
- Date and Time: Saturday, September 14, 2024, 12 – 1 pm CET
- Abstract Number: 5132, Poster 1020P
Swethajit Biswas, Chief Medical Officer of CDR-Life, commented, “The progress with CDR404 and CDR813 marks significant milestones in developing cutting-edge cancer treatments using our M-gager technology. Our TCEs are designed to target cancer-specific antigens with high specificity and potency, aiming to transform treatment options for patients with the HLA-A*02:01 genotype, prevalent in the U.S. and Europe.”
About CDR-Life CDR-Life focuses on creating highly targeted T cell engagers (TCEs) for treating solid tumors and autoimmune diseases. Using its M-gager® platform, the company develops TCEs against both intracellular and surface antigens with unparalleled specificity. CDR-Life’s collaboration with Boehringer Ingelheim on a Phase 2 trial molecule underscores its commitment to delivering impactful therapies. Supported by leading investors, CDR-Life aims to provide transformative medicines to patients worldwide.
